Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 41 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Double-blind Abatacept Clear all

Conditions: Rheumatoid Arthritis
Interventions: Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 35
States / cities: Huntsville, Alabama • La Jolla, California • Long Beach, California + 32 more

Conditions: Systemic Lupus Erythematosus
Interventions: Abatacept, Placebo; Biological · Other
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: Abatacept, Normal Saline, D5W; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more

Conditions: Alopecia Areata
Interventions: Abatacept, placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis, Chronic Hepatitis B
Interventions: Abatacept, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Psoriasis Vulgaris
Interventions: Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1996
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Psoriasis Vulgaris
Interventions: CTLA4Ig / Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1998
U.S. locations: 10
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, placebo, methotrexate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 19
States / cities: Huntsville, Alabama • Huntington Beach, California • Colorado Springs, Colorado + 15 more

Conditions: COVID-19, SARS-CoV-2
Interventions: Abatacept, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more

Conditions: Takayasu's Arteritis, Giant Cell Arteritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 15 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 8
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Belatacept, Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 17 more

Conditions: Lupus Nephritis
Interventions: BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 26
States / cities: Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 44
States / cities: Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more

Conditions: Giant Cell Arteritis
Interventions: Abatacept, Placebo, Glucocorticoid Treatment; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 13
States / cities: Phoenix, Arizona • Fullerton, California • West Hollywood, California + 10 more

Conditions: Psoriatic Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 19
States / cities: Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 19
States / cities: Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more

Search by objective public record fields.

The Study of Abatacept in Combination With Etanercept

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris

Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis